Results 21 to 30 of about 70,663 (209)

Classic and Activating Chimeric Antigen Receptors PD-1 as an Element of Multi-Target Approach to the Treatment of Hematological and Solid Neoplasms

Клиническая онкогематология, 2023
Aim. To generate anti-PD-L1 CAR-T effectors carrying extracellular domain PD-1 as antigen-recognizing site and to study their cytolytic activity as well as to functionally assess the anti-PD-L1 CAR-T effectors in vitro with a view to apply them in multi ...
Kseniya Aleksandrovna Levchuk, A. A. Goldaev, E. A. Stolyarova, P. A. Mateikovich, A. Kh. Valiullina, E. R. Bulatov, A. V. Petukhov, A. A. Daks, N. A. Barlev, E. V. Baidyuk, Ya. G. Toropova   +10 more
doaj   +1 more source

Nanobody based dual specific CARs [PDF]

, 2018
Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich, Bonte, Sarah, De Munter, Stijn, Goetgeluk, Glenn, Ingels, Joline, Kerre, Tessa, Pille, Melissa, Vandekerckhove, Bart, Weening, Karin   +8 more
core   +2 more sources

Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis

Nature Communications, 2022
Co-expression of PD-L1-specific chimeric switch receptors (CSRs) improves the antitumor effects of chimeric antigen receptor (CAR) T cells. Here, CSRs are shown to promote the differentiation of mesothelin-targeting CAR T cells into central memory-like ...
Le Qin, Yuanbin Cui, Tingjie Yuan, Dongmei Chen, Ruocong Zhao, Shanglin Li, Zhiwu Jiang, Qiting Wu, Youguo Long, Suna Wang, Zhaoyang Tang, Huixia Pan, Xiaoping Li, Wei Wei, Jie Yang, Xuequn Luo, Zhenfeng Zhang, Qiannan Tang, Pentao Liu, Robert Weinkove, Yao Yao, Dajiang Qin, Jean Paul Thiery, Peng Li   +23 more
doaj   +1 more source

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. [PDF]

, 2018
Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of
Avanzi, Mauro P, Brentjens, Renier J, Cheung, Kenneth, Daniyan, Anthony F, Li, Xinghuo, Park, Hyebin, Purdon, Terence J, Spitzer, Matthew H, van Leeuwen, Dayenne G, Wijewarnasuriya, Dinali P, Yeku, Oladapo   +10 more
core   +1 more source

Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells [PDF]

Cancers, 2021
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized adoptive cell therapy with impressive therapeutic outcomes of >80% complete remission (CR) rates in some haematological malignancies. Despite this, CAR T cell therapy for the treatment of solid tumours has invariably been unsuccessful in the clinic.
Ali Hosseini Rad S. M., Joshua Colin Halpin, Mojtaba Mollaei, Samuel W. J. Smith Bell, Nattiya Hirankarn, Alexander D. McLellan   +5 more
openaire   +2 more sources

Approved CAR T cell therapies [PDF]

, 2018
Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute ...
Kros, J.M. (Johan), Li, J. (Jin), Zheng, P.P. (Pingpin)   +2 more
core   +7 more sources

Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types [PDF]

, 2017
Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor ...
Aftimos, Philippe, Awada, Ahmad, Brayer, Jason B, Catala, Gaetan, Davila, Marco L, Gilham, David E, Hendlisz, Alain, Kerre, Tessa, Lehmann, Frederic F, Lonez, Caroline, Machiels, Jean-Pascal H, Odunsi, Kunle, Piette, Fanny, Sallman, David A, Van den Neste, Eric, Verma, Bikash   +15 more
core   +1 more source

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

Cell Transplantation, 2022
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang, Yuying Guo, Yinghua Ji, Yan Gao, Min Zhang, Yanting Liu, Wuling Zhu, Ping Lu   +7 more
doaj   +1 more source

Chimeric antigen receptors (CARs) from bench-to-bedside

Immunology Letters, 2013
Chimeric antigen receptors (CARs) combine the antigen specificity of an antibody with the biologic properties of T lymphocytes. While the concept has been developed more than 20 years ago, only in recent years the clinical application of this approach has produced remarkable objective clinical responses.
Barbara, Savoldo, Gianpietro, Dotti
openaire   +3 more sources

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]

, 2019
BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena, Eggert, Angelika, Flemmig, Carina, Grunewald, Laura, Henssen, Anton, Jensen, Michael C., Joussen, Antonia, Klaus, Anika, Künkele, Annette, Radke, Josefine, Rossig, Claudia, Schulte, Johannes H., Schumann, Elisa, Schwiebert, Silke, Winkler, Annika, Zirngibl, Felix   +15 more
core   +2 more sources